General Motors Co. (GM) Financials Nov 17, 2014, 7:56
General Motors Co. (GM) Financials Nov 17, 2014, 7:56 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for General Motors Co.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 104.59B 135.59B 150.28B 152.26B 155.43B
Cost of Goods Sold (COGS) incl. D&A 112.39B 118.94B 131.17B 135.24B 134.93B
COGS excluding D&A 101.27B 112.02B 123.83B 96.48B 126.89B
Depreciation & Amortization Expense 11.11B 6.92B 7.34B 38.76B 8.04B
Depreciation 9.49B 4.36B 5.55B 37.19B 6.76B
Amortization of Intangibles 1.63B 2.56B 1.8B 1.57B 1.28B
Gross Income (7.8B) 16.65B 19.11B 17.01B 20.5B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 12.17B 11.45B 12.11B 11.79B 12.32B
Research & Development 0 6.96B 8.12B 7.37B 7.2B
Other SG&A 12.17B 4.48B 3.98B 4.43B 5.12B
Other Operating Expense 192M 118M 58M 438M 0
Unusual Expense (126.11B) (552M) 1.33B 35.52B 3.27B
EBIT after Unusual Expense 126.11B 552M (1.33B) (35.52B) (3.27B)
Non Operating Income/Expense 13M 734M 458M 622M 830M
Non-Operating Interest Income 1.29B 465M 455M 343M 246M
Equity in Affiliates (Pretax) 1.38B 0 0 - 1.81B
Interest Expense 6.15B 1.1B 540M 489M 334M
Gross Interest Expense 6.15B 1.16B 631M 606M 415M
Interest Capitalized - 62M 91M 117M 81M
Pretax Income 102.49B 5.74B 5.99B (30.26B) 7.46B
Income Tax (2.17B) 672M (110M) (34.83B) 2.13B
Income Tax - Current Domestic (38M) (11M) (76M) 84M 54M
Income Tax - Current Foreign (101M) 441M 275M 646M 512M
Income Tax - Deferred Domestic (1.26B) (17M) (20M) (32.38B) 1.19B
Income Tax - Deferred Foreign (768M) 259M (289M) (3.18B) 375M
Income Tax Credits 0 - - - -
Equity in Affiliates 558M 1.44B 3.19B 1.56B -
Other After Tax Income (Expense) - 0 0 0 0
Consolidated Net Income 105.22B 6.5B 9.29B 6.14B 5.33B
Minority Interest Expense 396M 331M 97M (52M) (15M)
Net Income 104.82B 6.17B 9.19B 6.19B 5.35B
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 104.82B 6.17B 9.19B 6.19B 5.35B
Preferred Dividends 131M 1.5B 1.61B 1.33B 1.58B
Net Income Available to Common 104.69B 4.67B 7.59B 4.86B 3.77B
EPS (Basic) 167.90 3.11 4.94 3.10 2.71
Basic Shares Outstanding 623.53M 1.5B 1.54B 1.57B 1.39B
EPS (Diluted) 167.82 2.89 4.58 2.92 2.38
Diluted Shares Outstanding 623.82M 1.62B 1.67B 1.68B 1.68B
EBITDA (9.04B) 12.01B 14.29B 43.54B 16.22B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...
Continue Reading
Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...
Continue Reading
Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...
Continue Reading
What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...
Continue Reading
Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...
Continue Reading
Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...
Continue Reading
Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...
Continue Reading
IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...
Continue Reading
Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...
Continue Reading
Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...
Continue Reading
Top 5 Most Recently Viewed Articles
Animating a Vision for Better Relations In a world where tensions between law enforcement and the public can feel like walking on a tightrope, the National Police Association (NPA) decided to switch gears with an animated public service announcement (PSA). Aiming to foster better police-community relations, they rolled out a new TV campaign starring "Officer Mike," a...
Continue Reading
Growth of Mixed and Extended Reality Headsets Recent analyses indicate that the market for mixed and extended reality headsets is poised for significant growth in the upcoming years. This shift towards these technologies is set to transform how users interact with digital environments. Current Trends in Headset Shipments A recent report highlights that shipments of...
Continue Reading
Supernus Pharmaceuticals Makes Strategic Acquisition Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) has completed a significant acquisition, enhancing its portfolio with the addition of Sage Therapeutics, Inc. (NASDAQ: SAGE). This strategic move not only strengthens Supernus' existing product line but also diversifies its revenue sources, aligning with its long-term growth...
Continue Reading
Quiddity Engineering made waves when it appointed Ryan Ingram as the Division Manager for its new Environmental service line. This wasn't just some run-of-the-mill hire; it was a power move to ramp up their capabilities in tackling environmental challenges that clients face. You know how it goes—companies can’t afford to sit still in this game, especially with all the...
Continue Reading
Bringing Verzenios to the Forefront in China From San Francisco to Suzhou, the buzz is all about Innovent Biologics teaming up with Eli Lilly to push Verzenios (abemaciclib) deeper into the Chinese market. This collaboration is like fitting the final piece of a jigsaw puzzle. Innovent's got the ground troops ready with its robust commercialization engine, while Lilly...
Continue Reading